Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stevia venture

This article was originally published in The Tan Sheet

Executive Summary

A joint venture by stevia producer GLG Life Tech and fitness product firm Weider Global Nutrition aims to bring dietary and tabletop supplements made with stevia leaf extracts into international markets, GLG announces Sept. 9. GLG Weider Sweet Naturals Corp. will leverage the stevia extraction expertise of Vancouver, British Columbia-based GLG, and the sales and distribution capacities of Salt Lake City-based Weider to "provide consumers a great tasting, natural and zero-calorie alternative to artificial sweeteners and calorie-laden sugar," says GLG President Brian Palmieri. Though multiple U.S. companies are either marketing or developing stevia-based sweeteners, FDA has not declared the substance safe as a food additive and consumer groups have questioned stevia safety data (1"The Tan Sheet" Sept. 1, 2008, p. 16)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel